Home > Oncology > ASCO 2021 > Melanoma > Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Presented By
Dr Rodabe Amaria , MD Anderson Cancer Center, TX, USA
Conference
ASCO 2021
Trial
Phase 2
Neoadjuvant and adjuvant treatment with nivolumab plus the LAG-3 inhibitor relatlimab achieved high pathologic complete response (pCR) and major pathologic response rates with a favourable toxicity profile. This was shown in a multi-institutional, investigator-initiated, single-arm study. A pooled analysis of 192 patients from 6 trials has shown improved recurrence-free survival and overall survival in patients with clinical stage III melanoma who achieved a pCR after neoadjuvant immunotherapy or targeted therapy [1]. In addition, a combination of neoadjuvant immunotherapy regimens has shown robust pathologic response with acceptable toxicity in stage III melanoma patients [2]. Also, nivolumab combined with the LAG-3 antibody relatlimab has demonstrated a favourable toxicity profile and responses in both checkpoint-naïve and refractory metastatic melanoma [3]. To evaluate the efficacy and safety of neoadjuvant nivolumab plus relatlimab followed by ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on